Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications
Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children ≥2 years with cystic fibrosis: 96-week interim results from a phase 3 open-label extension study.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: January 30, 2026
Impact of elexacaftor/tezacaftor/ivacaftor on gastrointestinal outcomes, inflammation, exocrine pancreatic function and fat malabsorption: Report of PROMISE pediatric substudy.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: October 12, 2025
Elexacaftor/tezacaftor/ivacaftor is associated with long-term reduction in use of chronic respiratory therapies in cystic fibrosis.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: August 01, 2025
Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in 6- to 11-Year-Olds with Cystic Fibrosis: An Observational Study.
Journal: Annals of the American Thoracic Society
Published: June 20, 2025
Airway Disease Progression on Chest Computed Tomography in Children With Primary Ciliary Dyskinesia.
Airway Disease Progression on Chest Computed Tomography in Children With Primary Ciliary Dyskinesia.
Journal: Pediatric pulmonology
Published: April 30, 2025
Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial.
Journal: The Lancet. Respiratory medicine
Published: October 17, 2024
Comparison of Longitudinal Outcomes in Children with Primary Ciliary Dyskinesia and Cystic Fibrosis.
Comparison of Longitudinal Outcomes in Children with Primary Ciliary Dyskinesia and Cystic Fibrosis.
Journal: Annals of the American Thoracic Society
Published: October 09, 2024
Airway Disease in Children with Primary Ciliary Dyskinesia: Impact of Ciliary Ultrastructure Defect and Genotype.
Journal: Annals of the American Thoracic Society
Published: November 28, 2022
Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: April 10, 2022
Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.
Journal: American journal of respiratory and critical care medicine
Published: November 16, 2021
Impact of azithromycin on serum inflammatory markers in children with cystic fibrosis and new Pseudomonas.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: October 21, 2021
PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: December 02, 2020
Last Updated: 09/26/2026